神經內分泌腫瘤治療市場規模、佔有率和成長分析（按腫瘤類型、治療產品、部位、最終用途和地區分類）—產業預測（2026-2033 年）

全球神經內分泌腫瘤治療市場預計到 2024 年將達到 24.8 億美元，到 2025 年將達到 26.2 億美元，到 2033 年將達到 41.1 億美元，預測期（2026-2033 年）的複合年成長率為 5.8%。

神經內分泌腫瘤（NETs）通常起源於神經細胞或內分泌細胞，其在全球範圍內的發生率正在上升。類癌尤其常見於胃腸道、闌尾、直腸、胰臟和肺部。這些腫瘤可表現為良性或惡性，並可引起多種症狀，包括消化器官系統問題、慢性咳嗽和心血管疾病。由於研發投入的增加、創新治療方法的推出以及能夠實現早期檢測的診斷技術的進步，神經內分泌腫瘤治療市場預計將迎來顯著成長。這些因素共同推動了市場的動態，並為全球患者提供了更多有效的治療選擇。

全球神經內分泌腫瘤治療促進因素

全球神經內分泌腫瘤治療市場受到全球神經內分泌腫瘤（NETs）發生率和盛行率不斷上升的顯著影響。隨著越來越多的患者被診斷出患有這種罕見疾病，對有效治療方法的需求也日益成長。這種日益增強的認知和不斷上升的發病率推動了NET特異性藥物的問世，從而促進了市場成長。因此，治療方法滿足患者的需求，創新和標靶治療的需求日益迫切，這正在重塑市場格局，並推動神經內分泌腫瘤治療市場的發展，因為醫療服務提供者正在努力應對這一緊迫的醫療挑戰。

限制全球神經內分泌腫瘤治療市場的因素

全球神經內分泌腫瘤治療市場的成長可能面臨重大挑戰，原因在於開發有效治療方法的高成本以及這些療法可能帶來的副作用。接受治療的患者可能會出現多種不良反應，包括血糖值升高、膽結石形成以及胃腸道疾病（如腹脹和噁心）。這些因素可能導致患者和醫療服務提供者在選擇這些治療方法時猶豫不決，從而影響市場動態，並限制該行業在滿足未被滿足的需求方面的整體擴張。應對這些挑戰對於市場的未來發展至關重要。

全球神經內分泌腫瘤治療市場趨勢

全球神經內分泌腫瘤治療市場正經歷顯著成長，其中生長抑制素類似物（SSA）已成為領先的治療選擇。這些藥物因其能有效抑制腫瘤生長、緩解症狀並作為可靠的生物標記物，已成為許多患者的首選治療方法。 SSA憑藉其安全性和有效性，尤其適用於不適合放射線治療或手術的患者，已佔據可觀的市場佔有率。此外，正在進行的臨床試驗以及新型SSA製劑的核准將進一步鞏固其市場地位，展現出神經內分泌腫瘤治療領域蓬勃發展的市場格局。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 技術分析
• 監管分析
• 專利分析
• 案例研究

全球神經內分泌腫瘤治療市場規模（按腫瘤類型和複合年成長率分類）（2026-2033 年）

• 腦膜瘤
• 腎上腺癌
• 類癌腫瘤
• 副神經節瘤
• 嗜鉻細胞瘤
• 其他

全球神經內分泌腫瘤治療市場規模（依治療產品分類）及複合年成長率（2026-2033 年）

• 生長抑制素類似物（SSA）
• 標靶治療
• 其他

全球神經內分泌腫瘤治療市場規模（按部位和複合年成長率分類）（2026-2033 年）

• 肺
• 胰臟
• 冒號
• 小腸
• 直腸
• 胃
• 其他

全球神經內分泌腫瘤治療市場規模（按最終用途和複合年成長率分類）（2026-2033 年）

• 醫院
• 診所
• 其他

全球神經內分泌腫瘤治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Novartis AG（Switzerland）
• Bristol Myers Squibb Company（US）
• Pfizer Inc.（US）
• Boehringer Ingelheim International GmbH（Germany）
• Hutchison MediPharma Limited（China）
• AVEO Pharmaceuticals, Inc.（US）
• Ipsen Pharma（France）
• Eli Lilly and Company（US）
• Exelixis, Inc.（US）
• Jubilant Pharmova Limited（India）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Viatris Inc.（US）
• Thermo Fisher Scientific Inc.（US）
• Regeneron Pharmaceuticals, Inc.（US）
• Sun Pharmaceutical Industries Ltd.（India）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Lupin（India）
• Exact Sciences Corporation（US）
• Advanced Accelerator Applications（France）
• BioSynthema Inc.（US）

結論與建議

Global Neuroendocrine Tumors Treatment Market size was valued at USD 2.48 Billion in 2024 and is poised to grow from USD 2.62 Billion in 2025 to USD 4.11 Billion by 2033, growing at a CAGR of 5.8% during the forecast period (2026-2033).

The global prevalence of neuroendocrine tumors (NET), often arising from neurological and endocrine cells, is on the rise, with carcinoid tumors predominantly found in the gastrointestinal tract, as well as the appendix, rectum, pancreas, and lungs. These tumors may present as benign or malignant and can lead to various symptoms, including gastrointestinal issues, chronic coughing, and cardiovascular problems. The market for neuroendocrine tumor treatments is poised for substantial growth, driven by increased research and development investments, the introduction of innovative therapies, and advancements in diagnostic techniques that facilitate early detection. This combination of factors contributes to enhanced market dynamics and the proliferation of effective treatment options for patients globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neuroendocrine Tumors Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Neuroendocrine Tumors Treatment Market Segments Analysis

Global Neuroendocrine Tumors Treatment Market is segmented by Tumor Types, Treatment Products, Sites, End Uses and region. Based on Tumor Types, the market is segmented into Meningiomas, Adrenal Cancer, Carcinoid Tumors, Paraganglioma, Pheochromocytoma and Others. Based on Treatment Products, the market is segmented into Somatostatin Analogs (SSAs), Targeted Therapy and Others. Based on Sites, the market is segmented into Lung, Pancreas, Colon, Small Intestine, Rectum, Stomach and Others. Based on End Uses, the market is segmented into Hospitals, Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Neuroendocrine Tumors Treatment Market

The Global Neuroendocrine Tumors Treatment market is significantly influenced by the increasing incidence and prevalence of neuroendocrine tumors (NET) across the globe. As more individuals are diagnosed with this rare condition, there is a growing demand for effective treatment options. This heightened awareness and incidence drive the adoption of medications specifically designed for NET, contributing to market growth. The result is a rising urgency for innovative therapies and targeted treatments that cater to the needs of patients, ultimately shaping the landscape of the neuroendocrine tumors treatment market and fueling its advancement as healthcare providers seek to address this pressing medical challenge.

Restraints in the Global Neuroendocrine Tumors Treatment Market

The growth of the Global Neuroendocrine Tumors Treatment market is likely to face significant challenges due to the substantial costs associated with developing effective therapies and the potential side effects linked to these treatments. Patients undergoing treatment may experience various adverse effects, such as elevated blood sugar levels, gallstone formation, and gastrointestinal issues like bloating and nausea. These factors could deter both patients and healthcare providers from pursuing these therapies, thereby influencing market dynamics and limiting the overall expansion of the sector in response to unmet medical needs. Addressing these challenges will be crucial for future market development.

Market Trends of the Global Neuroendocrine Tumors Treatment Market

The Global Neuroendocrine Tumors Treatment market is experiencing significant growth, with somatostatin analogs (SSAs) emerging as the leading therapeutic option. These medications effectively manage tumor growth, alleviate symptoms, and serve as reliable biomarkers, making them preferred treatments for many patients. SSAs command a substantial revenue share in the market due to their safety and efficacy, particularly for those not suitable for radiotherapy or surgery. Additionally, the ongoing clinical trials and forthcoming approvals of novel SSA formulations promise to further enhance their market position, indicating a robust and dynamic landscape in neuroendocrine tumor therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Neuroendocrine Tumors Treatment Market Size by Tumor Types & CAGR (2026-2033)

• Market Overview
• Meningiomas
• Adrenal Cancer
• Carcinoid Tumors
• Paraganglioma
• Pheochromocytoma
• Others

Global Neuroendocrine Tumors Treatment Market Size by Treatment Products & CAGR (2026-2033)

• Market Overview
• Somatostatin Analogs (SSAs)
• Targeted Therapy
• Others

Global Neuroendocrine Tumors Treatment Market Size by Sites & CAGR (2026-2033)

• Market Overview
• Lung
• Pancreas
• Colon
• Small Intestine
• Rectum
• Stomach
• Others

Global Neuroendocrine Tumors Treatment Market Size by End Uses & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Others

Global Neuroendocrine Tumors Treatment Market Size & CAGR (2026-2033)

• North America (Tumor Types, Treatment Products, Sites, End Uses)
  • US
  • Canada
• Europe (Tumor Types, Treatment Products, Sites, End Uses)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Tumor Types, Treatment Products, Sites, End Uses)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Tumor Types, Treatment Products, Sites, End Uses)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Tumor Types, Treatment Products, Sites, End Uses)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hutchison MediPharma Limited (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AVEO Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Pharmova Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanced Accelerator Applications (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioSynthema Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations